1IA
RPRX icon

1620 Investment Advisors’s Royalty Pharma RPRX Stock Holding History

1620 Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26
Closed -$735 – 744
2024
Q3 		$735 Buy
+26
New +$720 ﹤0.01% 659

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1620 Investment Advisors's RPRX Position: Q4 2024 in Review

1620 Investment Advisors sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 26 shares — an estimated $735 sold.

1620 Investment Advisors first reported a position in RPRX in Q3 2024 and held it in 1 quarter. The position peaked at $735 in Q3 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • 1620 Investment Advisors reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • 1620 Investment Advisors sold 26 Royalty Pharma shares in Q4 2024, an estimated $735.
  • 1620 Investment Advisors first reported a position in Royalty Pharma in Q3 2024 and held it in 1 quarter.
  • 1620 Investment Advisors's Royalty Pharma position peaked at $735 in Q3 2024.
  • 417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on 1620 Investment Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.